AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31948302 — intervention group
Group type: EXPERIMENTAL
Intervention: External/internal Tiaoqiheying decoction
Number of subjects: 102
Study 31948302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 31948302 — intervention group
Group type: EXPERIMENTAL
Intervention: External Tiaoqiheying decoction
Number of subjects: 102
Study 31738759 — intervention group
Group type: EXPERIMENTAL
Intervention: Guppy fish
Number of subjects: 103
Study 31738759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen (PPF)
Number of subjects: 103
Study 31738759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Guppy fish and PPF)
Number of subjects: 103
Study 31738759 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education through health volunteers
Number of subjects: 103
Study 31738759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal communication through health volunteers
Number of subjects: 103
Study 27908900 — intervention group
Group type: EXPERIMENTAL
Intervention: Democratic therapeutic community (DTC) treatment
Number of subjects: 70
Study 27908900 — intervention group
Group type: COMPARATOR
Intervention: Crisis planning plus treatment as usual (TAU)
Number of subjects: 70
Study 25988762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia seed oil (7 kcal kg‐1)
Number of subjects: 24
Study 25988762 — intervention group
Group type: COMPARATOR
Intervention: Water alone (control)
Number of subjects: 24
Study 23160364 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60mg/d)
Number of subjects: 75
Study 23160364 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10mg/d)
Number of subjects: 75
Study 23160364 — intervention group
Group type: COMPARATOR
Intervention: No antidepressant therapy (control group)
Number of subjects: 75
Study 21770848 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behavior therapy (CBT) for GAD, 8-week treatment
Number of subjects: 89
Study 21770848 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 89
Study 19157347 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar animal sound (one of two sounds)
Number of subjects: 93
Study 19157347 — intervention group
Group type: EXPERIMENTAL
Intervention: Degraded versions of the animal sounds mixed with white noise
Number of subjects: 93
Study 19157347 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor task
Number of subjects: 93
Study 19157347 — intervention group
Group type: EXPERIMENTAL
Intervention: Degraded auditory stimulus test
Number of subjects: 93
Study 16990238 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoints Program
Number of subjects: 3743
Study 16990238 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 3743
Study 12820485 — intervention group
Group type: COMPARATOR
Intervention: CPT-11 alone
Number of subjects: 30
Study 12820485 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 plus MLT
Number of subjects: 30
Study 12820485 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 at 50% dose reduction
Number of subjects: 30
Study 11261630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 27
Study 11261630 — intervention group
Group type: COMPARATOR
Intervention: Standard closure (no glue)
Number of subjects: 27
Study 8651473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 1% nasal spray QID + astemizole
Number of subjects: 365
Study 8651473 — intervention group
Group type: COMPARATOR
Intervention: Astemizole alone
Number of subjects: 365
Study 8651473 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray + astemizole
Number of subjects: 365
Study 8651473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (nedocromil sodium + astemizole)
Number of subjects: 365
Study 1347103 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin daily
Number of subjects: 12
Study 1347103 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin daily
Number of subjects: 12
Study 6734045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (18.5 +/- 4 mg every 8 hr)
Number of subjects: 20
Study 6734045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6734045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 31903334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) only, 50 mg/kg administered intravenously before surgery
Number of subjects: 120
Study 31903334 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid combined with vitamin C (TXC), 50 mg/kg TA and 2 g vitamin C with 100 mL 0.9% saline administered before surgery and daily infusions post-operation
Number of subjects: 120
Study 31903334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TA and TXC)
Number of subjects: 120
Study 28922910 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A combined with vitamin B combined with recombinant human erythropoietin (group C)
Number of subjects: 150
Study 28922910 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A combined with recombinant human erythropoietin (group A)
Number of subjects: 150
Study 28922910 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B combined with recombinant human erythropoietin (group B)
Number of subjects: 150
Study 27815591 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-blended HXLPE
Number of subjects: 100
Study 27815591 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE
Number of subjects: 100
Study 25889308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (Period 1)
Number of subjects: 148
Study 25889308 — intervention group
Group type: COMPARATOR
Intervention: Placebo BID (Period 2)
Number of subjects: 148
Study 24086333 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral Tenofovir/Emtricitabine (TDF/FTC‐Truvada)
Number of subjects: 72
Study 24086333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 72
Study 24086333 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐coital dosing of Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 72
Study 24086333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20864577 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-primed autologous T-cell product
Number of subjects: 21
Study 20864577 — intervention group
Group type: COMPARATOR
Intervention: Nonspecifically primed autologous T-cell product
Number of subjects: 21
Study 19462826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 284
Study 19462826 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 2.5 mg
Number of subjects: 284
Study 19462826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 18046292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 50 mg
Number of subjects: 150
Study 18046292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15521923 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin
Number of subjects: 0
Study 12031997 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC insertion before induction of anesthesia
Number of subjects: 200
Study 12031997 — intervention group
Group type: COMPARATOR
Intervention: PAC insertion after induction of anesthesia
Number of subjects: 200
Study 9732632 — intervention group
Group type: EXPERIMENTAL
Intervention: Air bubble technique
Number of subjects: 0
Study 9732632 — intervention group
Group type: COMPARATOR
Intervention: Z-track technique
Number of subjects: 0
Study 8071268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 30
Study 3123091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA (50 mg over 2 hr)
Number of subjects: 34
Study 3123091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary rt-PA (50 mg over 2 hr)
Number of subjects: 34
Study 3123091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary rt-PA (100 mg over 5 hr)
Number of subjects: 34
Study 3123091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA (100 mg over 5 hr)
Number of subjects: 34
Study 3123091 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Intravenous and Intrapulmonary rt-PA)
Number of subjects: 34
Study 31801814 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus reuteri
Number of subjects: 0
Study 31801814 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 29899061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg) for four weeks before quitting
Number of subjects: 1792
Study 29899061 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard smoking cessation pharmacotherapy and behavioral support)
Number of subjects: 1792
Study 27583380 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surfactant plus inhaled nitric oxide
Number of subjects: 511
Study 27583380 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide alone
Number of subjects: 511
Study 27583380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheotomy
Number of subjects: 511
Study 25246645 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 41
Study 25246645 — intervention group
Group type: COMPARATOR
Intervention: IVMP
Number of subjects: 41
Study 24490521 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethl starch sodium solution (3 mL/times for 1-3 years old, 5 mL/times for 4-7 years old, 7 mL/times for 8-14 years old, 3 times/day) + inhaled budesonide
Number of subjects: 96
Study 24490521 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide (500 microg/times for 1-5 years old, 1 mg/times and 2 times/day for 6-14 years old)
Number of subjects: 96
Study 21714932 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 4002
Study 21714932 — intervention group
Group type: COMPARATOR
Intervention: Diet plus pravastatin
Number of subjects: 4002
Study 21714932 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4002
Study 21714932 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 4002
Study 21714932 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4002
Study 19236622 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 0
Study 19236622 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0
Study 19236622 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose > 8.0 mmol/l
Number of subjects: 0
Study 19236622 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose <= 8.0 mmol/l
Number of subjects: 0
Study 16551889 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (3000 U infused over 30 min before heparin administration and 24 h later)
Number of subjects: 16
Study 16551889 — intervention group
Group type: COMPARATOR
Intervention: Control (no antithrombin infusion)
Number of subjects: 16
Study 16551889 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 16
Study 14535902 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 1.5 mg x kg(‐1)
Number of subjects: 193
Study 14535902 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose midazolam (0.5-1.0 mg x kg(‐1))
Number of subjects: 193
Study 10700758 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of perforated peptic ulcers
Number of subjects: 36
Study 10700758 — intervention group
Group type: COMPARATOR
Intervention: Open repair of perforated peptic ulcers
Number of subjects: 36
Study 9376645 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin at 20:00 h on Days 1 to 15 (Melatonin 1st)
Number of subjects: 10
Study 9376645 — intervention group
Group type: COMPARATOR
Intervention: Placebo on Days 16 to 30 (Placebo 2nd)
Number of subjects: 10
Study 9376645 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2nd
Number of subjects: 10
Study 9376645 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1st
Number of subjects: 10
Study 7902484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate therapy (180 or 360 mg during 6 or 9 weeks)
Number of subjects: 20
Study 7902484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate therapy (45 mg every 3 months for 1 year)
Number of subjects: 20
Study 6780266 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CPAP (FIO2 = 0.3, PO2 > 50 torr) at a mean age of 7.1 hours
Number of subjects: 38
Study 6780266 — intervention group
Group type: COMPARATOR
Intervention: Late CPAP (FIO2 = 0.5, PO2 > 50 torr) at a mean age of 15.1 hours
Number of subjects: 38
Study 31493344 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-form and iterative formulas for sample size determination for hierarchical data
Number of subjects: 0
Study 31493344 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas for a four-level hierarchical linear model
Number of subjects: 0
Study 31493344 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices impacting standard errors (e.g., random intercept or slope variance at each level)
Number of subjects: 0
Study 31812311 — intervention group
Group type: EXPERIMENTAL
Intervention: CGBH-soaked pharyngeal packing
Number of subjects: 101
Study 31812311 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked pharyngeal packing
Number of subjects: 101
Study 28386783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, total dose of 30 mg perioperatively
Number of subjects: 110
Study 28386783 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucocorticoid)
Number of subjects: 110
Study 28386783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 110
Study 25886492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Personalised Decision Support (TPDS)
Number of subjects: 3408
Study 25886492 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Tailored Personalised Decision Support (NTPDS)
Number of subjects: 3408
Study 25886492 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 3408
Study 25886492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Personalised Decision Support (TPDS) and Non-Tailored PDS (NTPDS)
Number of subjects: 3408
Study 25886492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored messaging
Number of subjects: 3408
Study 23596788 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Taohe Chengqi Granule (MTCG) combined with intravenous dripping of mannitol
Number of subjects: 64
Study 23596788 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dripping of mannitol alone
Number of subjects: 64
Study 21233806 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle school-based obesity intervention program
Number of subjects: 450
Study 21233806 — intervention group
Group type: COMPARATOR
Intervention: Standard health curriculum (Control)
Number of subjects: 450
Study 19384225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoduodenal (ND) feedings
Number of subjects: 121
Study 19384225 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric (NG) feedings
Number of subjects: 121
Study 17192498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered as solution to the distal ileum
Number of subjects: 10
Study 17192498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered as solution to the ascending colon
Number of subjects: 10
Study 17192498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered as powder to the ascending colon
Number of subjects: 10
Study 17192498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered orally as an immediate-release tablet
Number of subjects: 10
Study 17141633 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel botulinum toxin type A (BTX‐A) and comprehensive rehabilitation
Number of subjects: 46
Study 17141633 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy (PT)
Number of subjects: 46
Study 14663611 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline‐irrigated cooled‐tip radiofrequency ablation (SICTRA)
Number of subjects: 113
Study 10355394 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II)
Number of subjects: 350
Study 10355394 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit (control group)
Number of subjects: 350
Study 7739262 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted lobectomy
Number of subjects: 61
Study 7739262 — intervention group
Group type: COMPARATOR
Intervention: Muscle-sparing thoracotomy and lobectomy
Number of subjects: 61
Study 2166720 — intervention group
Group type: EXPERIMENTAL
Intervention: N-methylformamide (N-MF)
Number of subjects: 54
Study 2166720 — intervention group
Group type: EXPERIMENTAL
Intervention: spirogermanium
Number of subjects: 54
Study 6756828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 74
Study 6756828 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 74
Study 6756828 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 74
Study 31012215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal barostat study (follow-up after 8-12 years)
Number of subjects: 26
Study 31012215 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QOL assessment (follow-up after 8-12 years)
Number of subjects: 26
Study 31012215 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of anxiety, depression, IBS symptom severity, or somatization (follow-up after 8-12 years)
Number of subjects: 26
Study 28074804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 30
Study 28074804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 30
Study 28074804 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 30
Study 28074804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1 mg/kg
Number of subjects: 30
Study 28074804 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study 25954849 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized heparin management (IHM)
Number of subjects: 120
Study 25954849 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis management (CHM)
Number of subjects: 120
Study 23962470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 10 mg with 0.5% bupivacaine 10 mg
Number of subjects: 80
Study 23962470 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 10 μg with 0.5% bupivacaine 10 mg
Number of subjects: 80
Study 23962470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 10 mg
Number of subjects: 80
Study 23962470 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 10 μg
Number of subjects: 80
Study 21372608 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + lifestyle (ML)
Number of subjects: 22
Study 21372608 — intervention group
Group type: COMPARATOR
Intervention: Placebo + lifestyle (PL)
Number of subjects: 22
Study 21372608 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in vitro)
Number of subjects: 22
Study 17923328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ketamine
Number of subjects: 18
Study 17923328 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study 17135672 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli-derived lipopolysaccharide (LPS)
Number of subjects: 2
Study 17135672 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae-derived 1,3 beta-glucan (BGL)
Number of subjects: 2
Study 17135672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LPS + BGL
Number of subjects: 2
Study 17135672 — intervention group
Group type: COMPARATOR
Intervention: PBS (control)
Number of subjects: 2
Study 12707865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor pain
Number of subjects: 100
Study 12707865 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 100
Study 10764171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal PCA with fentanyl (25 microg bolus, lockout interval 6 min)
Number of subjects: 48
Study 10764171 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA with fentanyl (17.5 microg bolus, lockout interval 6 min)
Number of subjects: 48
Study 10764171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intranasal and Intravenous PCA)
Number of subjects: 48
Study 8827547 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant therapy for hyaline membrane disease (HMD)
Number of subjects: 0
Study 1599072 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of pethidine added to 9 ml of 0.25% bupivacaine
Number of subjects: 49
Study 1599072 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of saline (control)
Number of subjects: 49
Study 6486080 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg, two daily doses)
Number of subjects: 0
Study 6486080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31517849 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable; systematic review and meta-analysis of existing studies
Number of subjects: 0
Study 29985782 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed auditory message
Number of subjects: 258
Study 29985782 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed written message
Number of subjects: 258
Study 29985782 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed auditory message
Number of subjects: 258
Study 29985782 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed written message
Number of subjects: 258
Study 27716290 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI Neurofeedback Training (NFT) in addition to treatment as usual
Number of subjects: 0
Study 27716290 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 24777150 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole IV bolus at a dose of 80 mg plus infusion at 8 mg/h for 72 h and oral placebo every 12 h (IVP group)
Number of subjects: 244